Societal CDMO Inc
NASDAQ:SCTL
Intrinsic Value
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). [ Read More ]
The intrinsic value of one SCTL stock under the Base Case scenario is 1.3 USD. Compared to the current market price of 1.08 USD, Societal CDMO Inc is Undervalued by 17%.
Valuation Backtest
Societal CDMO Inc
Run backtest to discover the historical profit from buying and selling SCTL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Societal CDMO Adjusts Guidance Amid Growth
2023-Q3 Earnings Call
Societal CDMO reported a revenue jump to $23.6 million for Q3 2023, up from $21.6 million the previous year, citing increased demand for Verapamil products. Despite the rise, a net loss widened to $4.6 million ($0.05 per diluted share) from $3.3 million ($0.06 per diluted share), and adjusted EBITDA fell to $2.8 million from $3.8 million. For the nine months, revenue inched up to $66.9 million from $65.9 million, while net loss also grew to $12.5 million. The company is streamlining operations, expecting to reduce annualized costs by $5.5 million and revising 2023 revenue guidance to $92-$94 million, with adjusted EBITDA projected at $11.5-$13 million.
Balance Sheet Decomposition
Societal CDMO Inc
Current Assets | 53.5m |
Cash & Short-Term Investments | 8.1m |
Receivables | 29.4m |
Other Current Assets | 16m |
Non-Current Assets | 100m |
PP&E | 54.8m |
Intangibles | 43.3m |
Other Non-Current Assets | 1.9m |
Current Liabilities | 50m |
Accounts Payable | 1.3m |
Accrued Liabilities | 11.4m |
Other Current Liabilities | 37.3m |
Non-Current Liabilities | 44.8m |
Long-Term Debt | 339k |
Other Non-Current Liabilities | 44.5m |
Earnings Waterfall
Societal CDMO Inc
Revenue
|
94.6m
USD
|
Cost of Revenue
|
-76.5m
USD
|
Gross Profit
|
18.1m
USD
|
Operating Expenses
|
-21.7m
USD
|
Operating Income
|
-3.6m
USD
|
Other Expenses
|
-9.7m
USD
|
Net Income
|
-13.3m
USD
|
Free Cash Flow Analysis
Societal CDMO Inc
What is Free Cash Flow?
SCTL Profitability Score
Profitability Due Diligence
Societal CDMO Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
Societal CDMO Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
SCTL Solvency Score
Solvency Due Diligence
Societal CDMO Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Societal CDMO Inc's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SCTL Price Targets Summary
Societal CDMO Inc
According to Wall Street analysts, the average 1-year price target for SCTL is 1.12 USD with a low forecast of 1.11 USD and a high forecast of 1.16 USD.
Ownership
SCTL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SCTL Price
Societal CDMO Inc
Average Annual Return | 21.99% |
Standard Deviation of Annual Returns | 143.4% |
Max Drawdown | -98% |
Market Capitalization | 113.2m USD |
Shares Outstanding | 105 573 000 |
Percentage of Shares Shorted | 0.17% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The company is headquartered in Exton, Pennsylvania and currently employs 258 full-time employees. The company went IPO on 2014-03-07. Societal CDMO is principally focused on solving various manufacturing problems. The company is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. In addition to its experience in handling Drug Enforcement Agency (DEA) controlled substances and developing and manufacturing modified-release dosage forms, the Company has the ability to deliver on its clients pharmaceutical development and manufacturing projects. The company conducts its operations in Gainesville, Georgia and San Diego, California.
Contact
IPO
Employees
Officers
The intrinsic value of one SCTL stock under the Base Case scenario is 1.3 USD.
Compared to the current market price of 1.08 USD, Societal CDMO Inc is Undervalued by 17%.